Three biotechs returned to the public markets with upsized IPOs totaling more than $850 million, extending a 2026 wave of large equity raises. Seaport Therapeutics and Hemab Therapeutics debuted with substantial gross proceeds, and the aftermarket reaction reinforced investor demand for late-stage pipelines and platform-heavy models. The IPO surge also reflects continuing interest in clinical-stage biotechnology despite ongoing debate about trial design, reimbursement, and the pace of label expansion in crowded oncology and neuroscience categories.